Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) EBITDA Margin (2018 - 2023)

Denali Therapeutics has reported EBITDA Margin over the past 6 years, most recently at 7779.24% for Q3 2023.

  • Quarterly EBITDA Margin fell 488860.0% to 7779.24% in Q3 2023 from the year-ago period, while the trailing twelve-month figure was 33218.0% through Jun 2024, down 3318371.0% year-over-year, with the annual reading at 41.66% for FY2023, 26294.0% up from the prior year.
  • EBITDA Margin was 7779.24% for Q3 2023 at Denali Therapeutics, down from 62.71% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 77.19% in Q4 2020 and troughed at 7002800.0% in Q1 2021.
  • The 5-year median for EBITDA Margin is 937.11% (2022), against an average of 380375.05%.
  • Year-over-year, EBITDA Margin plummeted -700121560bps in 2021 and then surged 700262921bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 1236.26% in 2019, then soared by 106bps to 77.19% in 2020, then tumbled by -900bps to 617.22% in 2021, then plummeted by -52bps to 937.11% in 2022, then crashed by -730bps to 7779.24% in 2023.
  • Per Business Quant, the three most recent readings for DNLI's EBITDA Margin are 7779.24% (Q3 2023), 62.71% (Q2 2023), and 299.97% (Q1 2023).